The Chase Group (TCG) is pleased to announce the successful recruitment of David Geller, MD as the Vice President, Pulmonary and Rare Diseases Clinical Development at Arcturus Therapeutics. Dr. Geller, known for his vast experience in pulmonology, has spent his career making a significant positive impact on children and adults with cystic fibrosis and chronic respiratory diseases. Joining the team at Arcturus uniquely positions Dr. Geller to accelerate the development of the next generation of mRNA medicines and have the potential to change the lives of patients suffering from diseases with significant unmet medical needs. In addition to guiding clinical project teams, Dr. Geller will provide strategic leadership within the Pulmonary and Rare Disease franchise ensuring the successful design and implementation of clinical development plans. The Chase Group was able to execute and complete this search in an expedited time frame given their depth of knowledge and network in the life science industry. TCG never loses sight of the profound impact their services have on the future success of an organization and looks forward to a continued partnership with Arcturus Therapeutics as they grow and unlock the potential of mRNA medicines. To learn more about collaborating with The Chase Group to build your executive team, please contact karen@chasegroup.com.
The Chase Group Successfully Places David Geller, MD as Head of Pulmonary & Rare Disease Clinical Development for Arcturus Therapeutics
The Chase Group (TCG) is pleased to announce the successful recruitment of David Geller, MD as the Vice President, Pulmonary and Rare Diseases Clinical Development at Arcturus Therapeutics. Dr. Geller, known for his vast experience in pulmonology, has spent his career making a significant positive impact on children and adults with cystic fibrosis and chronic respiratory diseases. Joining the team at Arcturus uniquely positions Dr. Geller to accelerate the development of the next generation of mRNA medicines and have the potential to change the lives of patients suffering from diseases with significant unmet medical needs. In addition to guiding clinical project teams, Dr. Geller will provide strategic leadership within the Pulmonary and Rare Disease franchise ensuring the successful design and implementation of clinical development plans. The Chase Group was able to execute and complete this search in an expedited time frame given their depth of knowledge and network in the life science industry. TCG never loses sight of the profound impact their services have on the future success of an organization and looks forward to a continued partnership with Arcturus Therapeutics as they grow and unlock the potential of mRNA medicines. To learn more about collaborating with The Chase Group to build your executive team, please contact karen@chasegroup.com.- Categories: Life Sciences, Research & Development
The Chase Group Successfully Completes Search for Vice President, Research & Development at Alexza Pharmaceuticals
Alexza Pharmaceuticals stands at the crossroads of innovation and advanced technology with a platform that has the potential to address unmet medical needs in neuroscience….
The Chase Group Successfully Places David Geller, MD as Head of Pulmonary & Rare Disease Clinical Development for Arcturus Therapeutics
The Chase Group (TCG) is pleased to announce the successful recruitment of David Geller, MD as the Vice President, Pulmonary and Rare Diseases Clinical Development…
Drug Safety Leadership Team Grows at Ionis Pharmaceuticals Through Continued Partnership with The Chase Group
Ionis Pharmaceuticals retained The Chase Group to identify and secure the next member of their drug safety leadership team to support a robust and continually…
The Chase Group Continues Successful Collaboration with Genmab Through Placement of Vice President, CDTL
The Chase Group, known for its thorough search capabilities and expertise in Life Sciences Executive Search, was retained by Genmab Pharmaceuticals to execute a critical…
The Chase Group Successfully Secures Vice President, Head of Medical Development for Checkmate Pharmaceuticals
Building on a 14+ year relationship with Chase, the Chief Medical Officer of Checkmate Pharmaceuticals retained The Chase Group to identify a critical hire for…
Search Executed by The Chase Group, Inc. Results in Successful Appointment of Dr. Christophe Hotermans as SVP, Global Medical Affairs for Akcea Therapeutics
The Chase Group was once again retained by Akcea Therapeutics to complete an extensive executive search on an accelerated timeline for a Senior Vice President,…